

ABSTRACT OF THE DISCLOSURE

The present invention provides a chimeric mouse/human antibody (ch-
5 mAb6B5) for treatment of abuse and toxicity of the arylcyclohexylamines class of drugs
(i.e., phencyclidine- or PCP-like drugs). This antibody comprises light and heavy chain
PCP binding regions of mouse mAb6B5, coupled to the light and heavy chain constant
regions of a human kappa IgG₂ or IgG₄ isoform. Also provided are the DNA and amino
acid sequences of the chimeric light and heavy chain of this antibody. Further provided are
10 data that demonstrate that the new chimeric antibody retains the high affinity and
specificity of a previously generated mouse anti-PCP monoclonal antibody (mAb6B5) yet
being minimally immunogenic since it has human immunoglobulin constant region. This
new medication would allow safe and effective treatment of PCP drug overdose, decrease
mortality, and reduce harmful effects due to excessive and prolonged PCP drug use.